Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03699956 · ClinicalTrials.gov registry record · Phase 3
RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer
A Phase 3 study, sponsored by EpicentRx.
- Terminated
- Registry status
- Phase 3
- Development phase
- 18
- Enrollment target
NCT03699956 is a Phase 3 study that was terminated before completion, run by EpicentRx. The registered enrollment target is 18 participants.
The verdict
NCT03699956, a Phase 3 study, was terminated before completion, sponsored by EpicentRx.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 18 participants
- Enrollment target
Study Summary
This Phase 3 study aims to find out whether RRx-001 + platinum chemotherapy is more effective than platinum chemotherapy alone in 3rd line or beyond small cell cancer.
Interventions
- DRUG Cisplatin/carboplatin plus etoposide
- COMBINATION_PRODUCT RRx-001 + eLOOP Device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2018-12-24 |
| Est. Completion | 2024-03-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03699956
The ClinicalTrials.gov registry entry for NCT03699956 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EpicentRx, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cisplatin/carboplatin plus etoposide is the first listed.
NCT03699956 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03699956 about?
NCT03699956 is a clinical study titled "RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer". This Phase 3 study aims to find out whether RRx-001 + platinum chemotherapy is more effective than platinum chemotherapy alone in 3rd line or beyond small cell cancer.
What is the current status of trial NCT03699956?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 18 participants. The study started on 2018-12-24. Estimated completion is 2024-03-01.
What interventions are being tested in trial NCT03699956?
The interventions under investigation include: Cisplatin/carboplatin plus etoposide (DRUG), RRx-001 + eLOOP Device (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03699956?
This trial is sponsored by EpicentRx, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.